| Added by | pmartino |
|---|---|
| Group name | EquipePM |
| Item Type | Journal Article |
| Title | Claudin gene expression profiles and clinical value in colorectal tumors classified according to their molecular subtype |
| Creator | Cherradi et al. |
| Author | Sara Cherradi |
| Author | Pierre Martineau |
| Author | Céline Gongora |
| Author | Maguy Del Rio |
| Abstract | Purpose: Colorectal cancer (CRC) is a heterogeneous disease that can be classified into distinct molecular subtypes. The aims of this study were 1) to compare claudin (CLDN) gene expression in CRC samples and normal colon mucosa, and then in the different CRC molecular subtypes, and 2) to assess their prognostic value. Patients and methods: CLDN expression in CRC samples was analyzed using gene expression data for a cohort of 143 primary CRC samples, and compared in the same CRC samples classified into different molecular subtypes (C1 to C6 according to the Marisa's classification, and CMS1 to CMS4 of the consensus classification). Comparison of CLDN expression in normal and tumor colon samples was also made on a smaller number of samples. Then, the relationship between CLDN expression profiles and overall survival (OS) and progression-free survival was examined. Results: Compared with normal mucosa, CLDN1 and CLDN2 were upregulated, whereas CLDN5, 7, 8, and 23 were downregulated in CRC samples. Variations in CLDN expression profiles were observed mainly in the CMS2/C1 and CMS4/C4 subtypes. Overall, expression of CLDN2 or CLDN4 alone had a strong prognostic value that increased when they were associated. In the CMS4/C4 subtypes, lower expressions of CLDN11, CLDN12, and CLDN23 were associated with longer OS. Conversely, in the CMS2 and C1 subtypes, low CLDN23 expression was associated with shorter OS and progression-free survival, suggesting a dual role for CLDN23 as a tumor suppressor/promoter in CRC. CLDN6 and CLDN11 had a prognostic value in the CMS2 and C4 subtypes, respectively. Conclusion: This analysis of CLDN gene expression profiles and prognostic value in CRC samples classified according to their molecular subtype shows that CRC heterogeneity must be taken into account when assessing CLDN potential value as prognostic markers or therapeutic targets. |
| Publication | Cancer Management and Research |
| Volume | 11 |
| Pages | 1337-1348 |
| Date | 2019 |
| Journal Abbr | Cancer Manag Res |
| Language | eng |
| DOI | 10.2147/CMAR.S188192 |
| ISSN | 1179-1322 |
| Library Catalog | PubMed |
| Call Number | IMPACT: 3.702 |
| Extra | PMID: 30863148 PMCID: PMC6389001 IMPACT: 3.702 |
| Tags | cancer, claudin, mabimprove, original, selection, siric, target, tight junction |
| Date Added | 2019/04/01 - 09:00:35 |
| Date Modified | 2021/03/05 - 10:43:22 |
| Notes and Attachments | Full Text (Attachment) PubMed entry (Attachment) |
Institut de Recherche en Cancérologie de
